share_log

HC Wainwright & Co. Reiterates Buy on Calliditas Therapeutics, Maintains $50 Price Target

Benzinga ·  Aug 21, 2023 06:08

HC Wainwright & Co. analyst Edwin Zhang reiterates Calliditas Therapeutics (NASDAQ:CALT) with a Buy and maintains $50 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment